PTC Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 64.46 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 5.38B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington’s disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich’s ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
Details
| Name | PTC Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 991 |
| Founded | 1998 |
| Ipo Date | 2013-06-20 |
| Ceo | Matthew Klein |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US69366J2006 |
| Cusip | 69366J200 |
| Cik | 0001070081 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Matthew B. Klein F.A.C.S., M.D., M.S. | Chief Executive Officer and Director |
| Dr. Allan Steven Jacobson Ph.D. | Co-Founder and Independent Director |
| Pierre Gravier M.S. | Chief Financial Officer |
| Dr. Neil Almstead Ph.D. | Chief Technical Operations Officer |
| Eric Pauwels | Chief Business Officer |
| Dr. Lee Scott Golden M.D., Ph.D. | Executive Vice President and Chief Medical Officer |
| Christine Utter CPA | Senior Vice President, Chief Accounting Officer and Head of People Services |
| Linda Montella Carter | Senior Vice President and Chief Information Officer |
| Ellen Cavaleri | Head of Investor Relations |
| Mark Elliott Boulding J.D. | Executive Vice President and Chief Legal Officer |
Contact
| Address | 500 Warren Corporate Center Drive, Warren, New Jersey 07059, United States |
| Phone | 908 222 7000 |
| Website | https://www.ptcbio.com |